DANIEL R. PASSERI - 16 Feb 2023 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
16 Feb 2023
Net transactions value
$0
Form type
4
Filing time
21 Feb 2023, 15:59:34 UTC
Previous filing
04 Apr 2022
Next filing
25 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +324,000 $0.000000 324,000 16 Feb 2023 Common Stock 324,000 $3.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023.